Pfizer Announces a **Quality Improvement Grant** RFP

**Innovative Solutions in Atopic Dermatitis and Alopecia Areata Management**

2022 I&I IT INNOVA-DERMA

**Competitive Grant Program – using Expert Review Panel**

### I. Background

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in practice as outlined in the specific RFP.

For all quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.
## II. Eligibility

<table>
<thead>
<tr>
<th>Geographic Scope:</th>
<th>Italy</th>
</tr>
</thead>
</table>
| Applicant Eligibility Criteria | • To be eligible:  
  • The institution and applicant must be based in the eligible country noted above.  
  • Only organizations are eligible to receive grants, not individuals or medical practice groups.  
  • Applicant must be affiliated with an Italian host institution.  
  • The applicant must have a medical degree (MD). |

## III. Requirements

<table>
<thead>
<tr>
<th>Date RFP Issued</th>
<th>25 March 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Area</td>
<td>Atopic Dermatitis and Alopecia Areata in adult patients</td>
</tr>
</tbody>
</table>
| Specific Area of Interest for this RFP: | The intent of this Request for Proposal (RFP) is to fund initiatives and projects focused on improving Atopic Dermatitis (AD) and Alopecia Areata (AA) management in adult patients through the implementation of innovative solutions aimed at:  
  • improving the referral of patients to Atopic Dermatitis (AD) / Alopecia Areata (AA) centers  
  • supporting collaboration/education among dermatologists to improve the management of Atopic Dermatitis (AD) or Alopecia Areata (AA) patients  
  • implementing multidisciplinary management of Atopic Dermatitis (AD) or Alopecia Areata (AA);  
  • optimizing differential diagnosis in Atopic Dermatitis (AD)  
  • addressing unmet needs in Alopecia Areata (AA)  
  • Projects must encompass systematic and continuous actions that directly impact patient care and include measurable outcomes via methodologically rigorous methods  
  • Projects must include an overt description of systemic improvements  
  • Priority will be given to projects that utilize digital solutions to improve |
Digital solutions may also involve the use of social networks:
- It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Healthcare professionals involved in the management of adult patients with Atopic Dermatitis (AD) or Alopecia Areata (AA)

- Individual projects requesting up to €50,000 will be considered. Pfizer anticipates awarding up to 5 grants. The estimated total available budget related to this RFP is €250,000.
- The amount of the grant Pfizer will be prepared to fund for any project will depend upon the external review panel’s evaluation of the proposal and costs involved and will be stated clearly in the approval notification.

RFP release date: 25 March 2022
- Full Proposal Deadline: 16 May 2022
  Please note the deadline is 23:59 Eastern Time (New York, GMT -5).
- Review of Full Proposals by External Review Panel: June 2022
- Anticipated Full Proposal Notification Date: July 2022
- The projects should last no longer than 18 months
- Grant funding will be distributed following execution of fully signed contract. The execution of fully signed contract must be completed within 90 days from receipt of the Approval Letter. Pfizer considers these terms non-negotiable for grant projects.

How to Submit:
- Please go to www.cybergrants.com/pfizer/QI and sign in. First-time users should click “REGISTER NOW”.
  [Note: there are individual portals for each grant application type (e.g., knowledge, LOI, research full proposal, and QI full proposal). Please be sure to use the URL above.]
- Click the “Start A New Quality Improvement Application” button.
- For the question “Competitive Grant?” select Yes
- Select the following Competitive Grant Program Name: 2022 I&I IT: INNOVA-DERMA
- Requirements for submission:
  Complete all required sections of the online application and upload your Full Proposal (see Appendix).
  If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.

IMPORTANT: Be advised applications submitted through the wrong portal will not be considered.
application type and/or submitted after the due date will not be reviewed by the committee.

**Questions:**
- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Ai Ping Lee (AiPing.Lee@pfizer.com), with the subject line “2022 I&I IT INNOVA-DERMA, March 2022.”

**Grant Agreements:**
- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click [here](#) to view the core terms of the agreement.
- Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution (including your legal department) is able and willing to abide by these terms before proceeding with submission of your application as they will need to be accepted in their entirety.

**Review and Approval Process**
- A specific grant program RFP uses an expert review panel (ERP) to make final grant decisions.
- The panels are comprised of professionals from the medical community with advanced degrees and expertise in particular clinical areas, or specific needs of a geographic region/learner group, or expertise in research, continuing professional development or quality improvement

**Mechanism by which Applicants will be Notified:**
- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.
# Appendix A
## Full Proposal Requirements

The Full Proposal will be accepted via the online application. Full Proposal documents should be no longer than 10-15 pages in length (12-point font and 1-inch margins) excluding Organization Detail and References. When answering the questions in the application please keep the following in mind:

| Goals and Objectives | • Briefly state the overall goal of the project. Also describe how this goal aligns with the focus of the RFP and the goals of the applicant organization(s).  
• List the *overall* objectives you plan to meet with your project both in terms of learning and expected outcomes. Objectives should describe the target population as well as the outcomes you expect to achieve as a result of conducting the project. |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Assessment of Need for the Project</td>
<td>• Please include a quantitative baseline data summary, initial metrics (e.g., quality measures), or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in <em>your</em> target area. Describe the source and method used to collect the data. Describe how the data was analyzed to determine that a gap existed. If a full analysis has not yet been conducted, please include a description of your plan to obtain this information.</td>
</tr>
<tr>
<td>Target Audience</td>
<td>• Describe the primary audience(s) targeted for this project. Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population</td>
</tr>
</tbody>
</table>
| Project Design and Methods | • Describe the planned project and the way it addresses the established need.  
• If your methods include educational activities, please describe succinctly the topic(s) and format of those activities |
| Innovation | • Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects or materials already developed.  
• Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project. |
<p>| Evaluation and Outcomes | • In terms of the metrics used for the needs assessment, describe how you will determine if the practice gap was addressed for the target group. Describe how you expect to collect and analyze the data. |</p>
<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticipated Project Timeline</td>
<td>• Provide an anticipated timeline for your project including project start/end dates</td>
</tr>
<tr>
<td>Additional Information</td>
<td>• If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here</td>
</tr>
<tr>
<td>Organization Detail</td>
<td>• Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project. Letters of support from partner organizations will be required at the Full Proposal stage only and should not be included with the LOI.</td>
</tr>
</tbody>
</table>
| Budget Detail                          | • A total amount requested is the only information needed for the LOI stage. Full Budget is not required. This amount can be adjusted at the Full Proposal stage as applicable.  
  • The budget amount requested must be in U.S. dollars (USD).  
  • While estimating your budget please keep the following items in mind:  
    o General organizational running costs such as insurances, heating, lighting, rent, building maintenance may be included. Pfizer does not provide funding for capital purchases (infrastructure expenses such as equipment, purchases of software or software licenses, technology or bricks and mortar). Equipment hire/leasing is acceptable and may be included in project budget. The inclusion of these costs cannot cause the amount requested to exceed the budget limit set forth in the RFP.  
    o The inclusion of these costs cannot cause the amount requested to exceed the budget limit set forth in the RFP.  
    o It should be noted that grants awarded through GMG cannot be used to purchase Pfizer therapeutic agents (prescription or non-prescription).  
  • Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent studies and projects. Please [click here](#) for details. |